Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan in HFpEF (PRISTINE-HF)
NCT04128891Phase 3Withdrawn
- Sponsor
- Flinders University
- Start
- Feb 2020
- Primary completion
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Flinders University. Primary endpoint: Effects of Sacubitril/Valsartan on microvascular function and ischaemia at 12 Months. Planned start Feb 2020; status: withdrawn.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04128891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128891.